A Diagnostic Rule That Guidelines Retired, Still Shaping a Treatment Decision
A single patient newly diagnosed with EoE after a second food-impaction visit. The disagreement isn't about whether a PPI trial is still required — that question was settled in 2018 — it's about whether it's still the right first move on the merits, once it stops being treated as mandatory.
Walter D. drives long-haul routes for a regional freight company and has had two food impactions fourteen months apart — the first one he treated as a fluke and didn't follow up on, the second one, this week, steak lodged badly enough to need endoscopic removal, that finally got him a real workup. Biopsies confirmed eosinophilic esophagitis at 50 eosinophils per high-power field, with the rings, furrows, and whitish exudates that go with it. He has no reflux symptoms at all, which used to matter more than it does now: for years, a formal PPI trial was required before EoE could even be diagnosed, specifically to rule out an entity called PPI-responsive esophageal eosinophilia as a separate condition from true EoE.
That requirement no longer exists. The 2018 AGREE international consensus conference removed the PPI trial as a diagnostic prerequisite entirely, once research showed PPI-responsive and PPI-unresponsive esophageal eosinophilia are clinically, endoscopically, and genetically indistinguishable — PPI-REE is now understood as a phenotype of EoE itself, not a different disease a trial needs to screen out. What that leaves unresolved is a separate, live question the consensus conference wasn't actually deciding: whether a PPI trial is still the right first-line treatment on its own merits, now that it's a therapeutic option rather than a diagnostic gate. PPIs work through a real anti-inflammatory mechanism in EoE, not just acid suppression — reducing IL-13-driven eotaxin-3 production directly — and clear roughly a third to half of patients on that basis alone. Walter, meanwhile, is a long-haul driver with irregular access to follow-up between routes and has already had two impactions. The first impaction, the one Walter shrugged off fourteen months ago, happened alone in his cab on a stretch of interstate with spotty cell coverage — he managed to clear it himself after several frightening minutes and never told anyone at the time, including his own doctor. He's mentioned that detail only now, prompted by the second event, and it reframes what "waiting eight weeks to see" actually asks of him: not just tolerating ordinary reflux symptoms, but living with a real, previously undisclosed risk of choking alone on a highway he already knows can happen again.
Diagnosis settled, first move still genuinely open
I'd start with an eight-week PPI trial. Since the 2018 AGREE consensus, this isn't a diagnostic hurdle anymore — it's a real treatment option, clearing something like a third to half of patients through genuine anti-inflammatory action on eotaxin-3, not just acid suppression. That's a legitimate first choice on the merits, not a formality we're stuck running.
I'd rather not spend eight weeks finding out. Walter has had two impactions fourteen months apart, drives long-haul routes with irregular access to follow-up between them, and an open-ended wait-and-see trial is a meaningfully different risk for him than for a patient who can be re-scoped easily next week if it doesn't work.
I’m not disputing the response rate you’re citing — I’m saying a one-in-three-to-one-in-two chance isn’t good enough odds to bet his third impaction on, given what a failed eight weeks actually costs someone in his situation.
I think the two of you actually agree more than this sounds like. Neither of you wants an open-ended eight-week wait if it isn't working — you're both describing a PPI trial with a hard failure trigger, you're just disagreeing about whether to run it at all.
Given his impaction history, I'd run the PPI trial, but pre-commit right now to switching to topical budesonide immediately at eight weeks if he isn't in histologic remission — not reassess openly at that point, decide today what an incomplete response means and act on it without a second round of deliberation.
Agreed: start an 8-week PPI trial with a pre-committed switch to budesonide oral suspension at 8 weeks if histologic remission isn't achieved, with the follow-up endoscopy scheduled around a confirmed home-time window in his driving route.
Not fully agreed, and worth naming:
The gastroenterologist would consider extending the trial briefly before switching, arguing partial response is meaningfully different from no response at all.
The allergist would hold to the pre-committed switch regardless, arguing his impaction history is exactly why the trigger was set in advance rather than left to be renegotiated at the eight-week visit.
The pre-commitment itself was agreed on as the right structure. What counts as meeting it — full remission only, or a good-enough partial response — wasn't fully settled, and was flagged for the eight-week visit rather than decided today.